Enzymatica AB

ENZY

SE0003943620

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:30 2024-05-31 EDT			5-day change	1st Jan Change
3.16 ^SEK	+7.85%		+9.34%	-19.90%

04-25	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-27	Enzymatica AB Announces Composition of Nomination Committee	CI

Enzymatica AB Provides Earnings Guidance for the Year 2026

November 02, 2021 at 03:45 am

Enzymatica AB provided earnings guidance for the year 2026. For the year, the company expects net sales amounting to at least SEK 600 million.

Latest news about Enzymatica AB

Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Enzymatica AB Announces Composition of Nomination Committee	03-27	CI
Enzymatica Obtains CE Marking for ColdZyme Mouth Spray	03-11	MT
Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-16	CI
Enzymatica AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Enzymatica’s Oral Spray Trial Reduces Viral Load in Common Colds	23-09-21	MT
Enzymatica AB Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat	23-09-21	CI
Enzymatica AB Announces New Study	23-08-22	CI
Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-18	CI
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Enzymatica AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Enzymatica AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Enzymatica AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Enzymatica Surges 35% After New Study Confirms ColdZyme Stops Omicron From Infecting Human Cells	22-11-01	MT
Enzymatica AB(OM:ENZY) dropped from S&P Global BMI Index	22-09-19	CI
Enzymatica Raises $7 Million Via Rights Issue	22-08-26	MT
Enzymatica To Boost Financial Position Via $7 Million Rights Offering	22-07-19	MT
Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-19	CI
Enzymatica AB Announces New Data from an Ongoing In-Vitro Study	22-06-23	CI
Enzymatica AB Appoints Moa Fransson as New Member of the Board	22-04-28	CI
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Enzymatica Rises 7% Ahead Of Mouth Spray Launch In Turkey	22-04-04	MT
Enzymatica AB Announces Mouth Spray Product Will Be Marketed, Sold, and Distributed in Turkey by Sanofi Consumer Health Care	22-04-04	CI
Enzymatica AB's Mouth Spray to Be Launches in Turkey	22-04-04	CI
Enzymatica and Sanofi Launches Mouth Spray in Mexico	22-03-03	CI

Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

Sector

Pharmaceuticals

Calendar

2024-07-18 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Enzymatica AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ENZYMATICA AB	-19.90%	47.97M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals

Enzymatica AB

Equities

ENZY

SE0003943620

Pharmaceuticals

Enzymatica AB Provides Earnings Guidance for the Year 2026

Latest news about Enzymatica AB

Chart Enzymatica AB

Company Profile

Income Statement Evolution

Ratings for Enzymatica AB

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals